An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization

Throughout the COVID-19 pandemic, many prophylactic and therapeutic drugs have been evaluated and introduced. Among these treatments, monoclonal antibodies (mAbs) that bind to and neutralize SARS-CoV-2 virus have been applied as complementary and alternative treatments to vaccines. Although differen...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Fu-Fei, Liang, Kang-Hao, Kumari, Monika, Chen, Wan-Yu, Lin, Hsiu-Ting, Cheng, Chao-Min, Tao, Mi-Hua, Wu, Han-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526872/
https://www.ncbi.nlm.nih.gov/pubmed/36198358
http://dx.doi.org/10.1016/j.ijpharm.2022.122256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526872/
https://www.ncbi.nlm.nih.gov/pubmed/36198358
http://dx.doi.org/10.1016/j.ijpharm.2022.122256

Ejemplares similares